Results Of A Prospective, Randomized, Open-Label Phase 3 Study Of Ruxolitinib (Rux) In Polycythemia Vera (Pv) Patients Resistant To Or Intolerant Of Hydroxyurea (Hu): The Response Trial
JOURNAL OF CLINICAL ONCOLOGY（2014）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要